Chao He1, Zhenyu Sun1, Robert M Hoffman2,3, Zhijian Yang2, Yuhang Jiang4, Lei Wang4, Yongqiang Hao4. 1. Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China. 2. AntiCancer, Inc., San Diego, CA, U.S.A. 3. Department of Surgery, University of California, San Diego, CA, U.S.A. 4. Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China xhaka2016@163.com wanglei12041985@163.com haoyq1664@sh9hospital.org.
Abstract
BACKGROUND/AIM: Osteosarcoma (OS) is a diagnosed primary cancer of the bone. Despite the great advances that have been made during the past decades in OS therapy, drug resistance and tumor recurrence are still major problems. It is urgent to find novel strategies to overcome drug resistance in order to prolong the survival time of OS patients. MATERIALS AND METHODS: Cell viability was investigated by the cell count kit-8 (CCK-8) and colony formation assays. P-Glycoprotein (P-gp) expression was analyzed by RT-qPCR and western blot. A xenograft mouse model was used to identify the synergistic efficacy of a P-gp inhibitor with cisplatin. Student's t-test was used to determine statistically significant differences. RESULTS: P-gp expression levels were associated with cisplatin efficacy in OS patients. OS cells with higher P-gp expression were more resistant to cisplatin. Knockdown or inhibition of P-gp sensitized OS cells to cisplatin. CONCLUSION: Down-regulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance. Copyright
BACKGROUND/AIM: Osteosarcoma (OS) is a diagnosed primary cancer of the bone. Despite the great advances that have been made during the past decades in OS therapy, drug resistance and tumor recurrence are still major problems. It is urgent to find novel strategies to overcome drug resistance in order to prolong the survival time of OS patients. MATERIALS AND METHODS: Cell viability was investigated by the cell count kit-8 (CCK-8) and colony formation assays. P-Glycoprotein (P-gp) expression was analyzed by RT-qPCR and western blot. A xenograft mouse model was used to identify the synergistic efficacy of a P-gp inhibitor with cisplatin. Student's t-test was used to determine statistically significant differences. RESULTS:P-gp expression levels were associated with cisplatin efficacy in OS patients. OS cells with higher P-gp expression were more resistant to cisplatin. Knockdown or inhibition of P-gp sensitized OS cells to cisplatin. CONCLUSION: Down-regulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance. Copyright
Authors: Magdalena Mizerska-Kowalska; Sylwia Sowa; Beata Donarska; Wojciech Płaziński; Adrianna Sławińska-Brych; Aleksandra Tomasik; Anna Ziarkowska; Krzysztof Z Łączkowski; Barbara Zdzisińska Journal: Int J Mol Sci Date: 2022-06-16 Impact factor: 6.208
Authors: José Manuel Casanova; Jani-Sofia Almeida; John David Reith; Luana Madalena Sousa; Ruben Fonseca; Paulo Freitas-Tavares; Manuel Santos-Rosa; Paulo Rodrigues-Santos Journal: Cancers (Basel) Date: 2021-12-02 Impact factor: 6.639